No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients

Sarrazin C, Cooper CL, Manns MP, et al. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. J Hepatol. 2018;69(6):1221-1230.

Publication Type:

Journal Article

Authors:

Sarrazin, C; Cooper, CL; Manns, MP; et, al

Source:

J Hepatol, Volume 69, Issue 6, p.1221-1230 (2018)

Cited On:

Export Citation:
RIS Format
Top